文献速递心境障碍

重新评估抗抑郁药疗效与可预测性:症状聚类方法

Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach.
PubMed 文献 · JAMA Psychiatry · 2017-01-01

该研究利用STAR*D试验(n=4039)识别抑郁症状聚类,并在CO-MED试验(n=640)中重复验证,再通过混合效应模型分析两个试验(n=4706)和7项度洛西汀3期试验(n=2515)的疗效差异。结果显示抗抑郁药对核心情绪症状的疗效优于睡眠或非典型症状,且药物间疗效差异常大于药物与安慰剂间的差异。

要点

  • 抑郁症状可稳定聚类为3组,并在不同量表和样本中重复。
  • 抗抑郁药对核心情绪症状疗效优于睡眠或非典型症状。
  • 药物间疗效差异常大于药物与安慰剂间的差异。

核心结论

  • 抑郁严重程度量表可产生统计可靠的症状聚类,且不同聚类对治疗的反应性存在差异,药物间差异常大于药物与安慰剂差异。

研究设计与样本

  • 研究使用STAR*D试验(n=4039)患者报告数据识别症状聚类,并在CO-MED试验(n=640)中重复验证。
  • 采用混合效应回归分析意向性治疗数据(两个试验n=4706,7项度洛西汀3期试验n=2515)评估症状聚类反应轨迹。

主要发现

  • 在STAR*D的QIDS-SR量表基线中识别出3个症状聚类,该3聚类方案在CO-MED中重复验证,且在HAM-D量表中类似。
  • 抗抑郁药总体(9种治疗中的8种)对核心情绪症状的疗效优于对睡眠或非典型症状的疗效。
  • 高剂量度洛西汀在治疗核心情绪症状上优于艾司西酞普兰(效应量2.3 HAM-D分,95%CI 1.6至3.1,P<.001),而艾司西酞普兰与安慰剂无显著差异(效应量0.03 HAM-D分,95%CI -0.7至0.8,P=.94)。

关键数值与推荐

  • 使用QIDS-SR的12个条目和HAM-D的14个条目评估症状严重程度,分数越高表示症状越重。
  • 高剂量度洛西汀对比艾司西酞普兰治疗核心情绪症状的效应量为2.3 HAM-D分(95%CI 1.6至3.1,P<.001)。
  • 艾司西酞普兰对比安慰剂的效应量为0.03 HAM-D分(95%CI -0.7至0.8,P=.94)。

临床怎么用

  • 临床选择抗抑郁药时可根据症状聚类针对性选药,针对核心情绪症状可能获得更大获益。
  • 药物间疗效差异可能大于药物与安慰剂的差异,提示优化药物选择的重要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Depressive severity is typically measured according to total scores on questionnaires that include a diverse range of symptoms despite convincing evidence that depression is not a unitary construct. When evaluated according to aggregate measurements, treatment efficacy is generally modest and differences in efficacy between antidepressant therapies are small. OBJECTIVES: To determine the efficacy of antidepressant treatments on empirically defined groups of symptoms and examine the replicability of these groups. DESIGN, SETTING, AND PARTICIPANTS: Patient-reported data on patients with depression from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (n = 4039) were used to identify clusters of symptoms in a depressive symptom checklist. The findings were then replicated using the Combining Medications to Enhance Depression Outcomes (CO-MED) trial (n = 640). Mixed-effects regression analysis was then performed to determine whether observed symptom clusters have differential response trajectories using intent-to-treat data from both trials (n = 4706) along with 7 additional placebo and active-comparator phase 3 trials of duloxetine (n = 2515). Finally, outcomes for each cluster were estimated separately using machine-learning approaches. The study was conducted from October 28, 2014, to May 19, 2016. MAIN OUTCOMES AND MEASURES: Twelve items from the self-reported Quick Inventory of Depressive Symptomatology (QIDS-SR) scale and 14 items from the clinician-rated Hamilton Depression (HAM-D) rating scale. Higher scores on the measures indicate greater severity of the symptoms. RESULTS: Of the 4706 patients included in the first analysis, 1722 (36.6%) were male; mean (SD) age was 41.2 (13.3) years. Of the 2515 patients included in the second analysis, 855 (34.0%) were male; mean age was 42.65 (12.17) years. Three symptom clusters in the QIDS-SR scale were identified at baseline in STAR*D. This 3-cluster solution was replicated in CO-MED and was similar for the HAM-D scale. Antidepressants in general (8 of 9 treatments) were more effective for core emotional symptoms than for sleep or atypical symptoms. Differences in efficacy between drugs were often greater than the difference in efficacy between treatments and placebo. For example, high-dose duloxetine outperformed escitalopram in treating core emotional symptoms (effect size, 2.3 HAM-D points during 8 weeks, 95% CI, 1.6 to 3.1; P < .001), but escitalopram was not significantly different from placebo (effect size, 0.03 HAM-D points; 95% CI, -0.7 to 0.8; P = .94). CONCLUSIONS AND RELEVANCE: Two common checklists used to measure depressive severity can produce statistically reliable clusters of symptoms. These clusters differ in their responsiveness to treatment both within and across different antidepressant medications. Selecting the best drug for a given cluster may have a bigger benefit than that gained by use of an active compound vs a placebo.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Chekroud AM, Gueorguieva R, Krumholz HM, et al. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. JAMA Psychiatry. 2017. PMID: 28241180. doi:10.1001/jamapsychiatry.2017.0025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。